Citadel Advisors’s LeMaitre Vascular LMAT Stock Holding History

Citadel Advisors’s Portfolio LMAT Stock Details LMAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$317K	Buy	3,300 +400	+14%	+$41K	﹤0.01%	10995
2026 Q1	$317K	Buy	2,900 +200	+7%	+$19.1K	﹤0.01%	10360
2025 Q4	$219K	Buy	+2,700	New	+$232K	﹤0.01%	10847
2025 Q2	–	Sell	-400	Closed	-$33.6K	–	13961
2025 Q1	$33.6K	Sell	400 -2,500	-86%	-$233K	﹤0.01%	12704
2024 Q4	$267K	Hold	2,900	–	–	﹤0.01%	9890
2024 Q3	$269K	Buy	2,900 +2,000	+222%	+$173K	﹤0.01%	9547
2024 Q2	$74.1K	Sell	900 -1,900	-68%	-$140K	﹤0.01%	11301
2024 Q1	$186K	Buy	2,800 +2,200	+367%	+$136K	﹤0.01%	10433
2023 Q4	$34.1K	Buy	600 +200	+50%	+$10.5K	﹤0.01%	12152
2023 Q3	$21.8K	Sell	400 -300	-43%	-$17.8K	﹤0.01%	12563
2023 Q2	$47.1K	Sell	700 -900	-56%	-$54.9K	﹤0.01%	11869
2023 Q1	$82.4K	Buy	+1,600	New	+$77.7K	﹤0.01%	11518
2022 Q1	–	Sell	-6,600	Closed	-$332K	–	14161
2021 Q4	$332K	Buy	+6,600	New	+$341K	﹤0.01%	10703
2021 Q3	–	Sell	-4,400	Closed	-$268K	–	14292
2021 Q2	$268K	Buy	+4,400	New	+$234K	﹤0.01%	11535

Other funds holding LMAT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CCM

Copeland Capital Management Conshohocken, Pennsylvania $4.87B AUM 31.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Citadel Advisors's LMAT Position: Q2 2026 in Review

Citadel Advisors reduced its LeMaitre Vascular (LMAT) stake by 56% in Q2 2026, selling an estimated $5.56M and leaving 42,833 shares worth $4.11M. The position accounts for ﹤0.01% of the portfolio, ranked #5075.

Citadel Advisors first reported a position in LMAT in Q4 2015 and has held it in 38 quarters since. The position peaked at $10.6M in Q1 2026. 326 funds tracked by Wall St. Rank hold LMAT as of Q2 2026.

Citadel Advisors held 42,833 shares of LeMaitre Vascular worth $4.11M as of Q2 2026.
Citadel Advisors sold 54,250 LeMaitre Vascular shares in Q2 2026, an estimated $5.56M.
LeMaitre Vascular made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #5075 holding.
Citadel Advisors first reported a position in LeMaitre Vascular in Q4 2015 and has held it in 38 quarters since.
Citadel Advisors's LeMaitre Vascular position peaked at $10.6M in Q1 2026.
326 funds tracked by Wall St. Rank held LeMaitre Vascular as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.